Skip to main content
October 14, 2020
Consistent participation in extracurricular sports during the elementary school years predicted fewer attention-deficit/hyperactivity disorder (ADHD) symptoms at age 12 in girls—but not in boys, according to a study in Preventive Medicine.
September 28, 2020
Children with attention-deficit/hyperactivity disorder (ADHD) who are African American appear to have key genetic differences from those who are Caucasian, according to a study published in Scientific Reports.
September 21, 2020
Exposure to endocrine-disrupting chemicals during adolescence may be associated with behaviors characteristic of attention-deficit/hyperactivity disorder, according to a study published online in JAMA Network Open. 
September 10, 2020
AR19, an investigational stimulant for attention-deficit/hyperactivity disorder (ADHD), improved symptoms in adults with ADHD in a Phase 3 trial, according to a poster presented at Psych Congress 2020.
September 01, 2020
Attention-deficit/hyperactive disorder (ADHD) and narcolepsy may share genetic links, according to an analysis of polygenic risk scores published online in the journal Translational Psychiatry.
August 19, 2020
Treatment with a central stimulant may reduce the risk of suicide attempt and nonsuicidal self-injury in adults with bipolar disorder and attention-deficit/hyperactivity disorder. 
August 10, 2020
Attentional behaviors observed in babies at 12 months of age appear to predict behaviors related to attention-deficit/hyperactivity disorder (ADHD) at 4.5 years of age.
July 21, 2020
Childhood neurocognitive markers may be able to help identify siblings of people with attention-deficit/hyperactivity disorder (ADHD) who will develop late-onset ADHD, researchers found in a study published in The Journal of Child Psychology and Psychiatry.
July 15, 2020
A multidisciplinary group of experts reached a high level of consensus on 36 of 37 statements for the screening, diagnosis, and treatment of adolescents with concurrent attention-deficit/hyperactivity disorder and substance use disorder.
July 07, 2020
Centanafadine, a novel investigational compound for the treatment of attention-deficit/hyperactivity disorder in adults, demonstrated statistically significant improvements compared with placebo in phase 3 clinical trials, the maker announced.
Back to Top